XML 57 R10.htm IDEA: XBRL DOCUMENT

Inventory

6 Months Ended

Jun. 30, 2014

(4)

Inventory

After approval of Vascepa on July 26, 2012 by the FDA, the Company began capitalizing its purchases of saleable inventory of Vascepa from suppliers that have been qualified by the FDA. Inventories consist of the following (in thousands):


	June 30, 2014		December 31, 2013
Raw materials, current	$	796	$	4,246
Work in process		12,432		11,310
Finished goods		3,915		5,026
Finished goods inventory held by others		—		627

Total inventory, current		17,143		21,209

Raw materials, long-term		—		5,482

Total inventory	$	17,143	$	26,691

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details